KR101849801B1 - 함질소 지환식 골격을 갖는 일본쇄 핵산 분자 - Google Patents

함질소 지환식 골격을 갖는 일본쇄 핵산 분자 Download PDF

Info

Publication number
KR101849801B1
KR101849801B1 KR1020137004646A KR20137004646A KR101849801B1 KR 101849801 B1 KR101849801 B1 KR 101849801B1 KR 1020137004646 A KR1020137004646 A KR 1020137004646A KR 20137004646 A KR20137004646 A KR 20137004646A KR 101849801 B1 KR101849801 B1 KR 101849801B1
Authority
KR
South Korea
Prior art keywords
region
nucleic acid
acid molecule
expression
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137004646A
Other languages
English (en)
Korean (ko)
Other versions
KR20130095738A (ko
Inventor
다다아키 오기
히로타케 하야시
히사오 시로즈
도모히로 하마사키
아키히로 이토
히로시 스즈키
Original Assignee
가부시키가이샤 보낙
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 보낙 filed Critical 가부시키가이샤 보낙
Publication of KR20130095738A publication Critical patent/KR20130095738A/ko
Application granted granted Critical
Publication of KR101849801B1 publication Critical patent/KR101849801B1/ko
Assigned to 도레이 카부시키가이샤 reassignment 도레이 카부시키가이샤 권리의 전부이전등록 Assignors: 가부시키가이샤 보낙
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020137004646A 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자 Expired - Fee Related KR101849801B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2010174915 2010-08-03
JPJP-P-2010-174915 2010-08-03
JP2010230806 2010-10-13
JPJP-P-2010-230806 2010-10-13
JPJP-P-2010-269823 2010-12-02
JP2010269823 2010-12-02
JP2011152381 2011-07-08
JPJP-P-2011-152381 2011-07-08
PCT/JP2011/067292 WO2012017919A1 (ja) 2010-08-03 2011-07-28 含窒素脂環式骨格を有する一本鎖核酸分子

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020187010011A Division KR101894702B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
KR1020187010010A Division KR101894701B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자

Publications (2)

Publication Number Publication Date
KR20130095738A KR20130095738A (ko) 2013-08-28
KR101849801B1 true KR101849801B1 (ko) 2018-04-17

Family

ID=45559420

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137004646A Expired - Fee Related KR101849801B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
KR1020187010011A Expired - Fee Related KR101894702B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
KR1020187010010A Expired - Fee Related KR101894701B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187010011A Expired - Fee Related KR101894702B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
KR1020187010010A Expired - Fee Related KR101894701B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자

Country Status (10)

Country Link
US (3) US8691782B2 (enExample)
EP (4) EP2436767B1 (enExample)
JP (3) JP4965745B2 (enExample)
KR (3) KR101849801B1 (enExample)
CN (3) CN104059911B (enExample)
DK (1) DK2674494T3 (enExample)
ES (4) ES2533129T3 (enExample)
PT (1) PT2674494E (enExample)
TW (2) TWI572716B (enExample)
WO (1) WO2012017919A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533129T3 (es) 2010-08-03 2015-04-07 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
EP3254700B1 (en) 2012-03-04 2019-10-23 Bonac Corporation Micro-rna inhibitor
WO2013133393A1 (ja) * 2012-03-07 2013-09-12 学校法人東京医科大学 Ｖｅｇｆ遺伝子の発現抑制用一本鎖核酸分子
JP6283859B2 (ja) * 2012-03-29 2018-02-28 国立大学法人九州大学 ペリオスチン遺伝子の発現抑制核酸分子、ペリオスチン遺伝子の発現抑制方法、およびその用途
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
WO2015046451A1 (ja) * 2013-09-27 2015-04-02 株式会社アクアセラピューティクス 眼科疾患を除くペリオスチン発現に起因する疾患用医薬、およびその用途
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
SG10201805087VA (en) * 2013-12-27 2018-07-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
WO2015099188A1 (ja) * 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
HK1244035A1 (en) * 2014-12-15 2018-07-27 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
WO2016104775A1 (ja) 2014-12-27 2016-06-30 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
HK1244030A1 (en) * 2014-12-29 2018-07-27 东丽株式会社 Composition containing nucleic acid molecule stably
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
JPWO2016167366A1 (ja) * 2015-04-17 2018-04-05 国立大学法人 東京大学 眼疾患治療剤
EP3369816B1 (en) 2015-10-30 2024-03-13 Toray Industries, Inc. Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene
JP6634095B2 (ja) * 2015-12-29 2020-01-22 国立大学法人北海道大学 プロレニン遺伝子またはプロレニン受容体遺伝子の発現を抑制する一本鎖核酸分子およびその用途
EP3409779A4 (en) * 2016-01-26 2019-07-03 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2017131237A1 (ja) * 2016-01-30 2017-08-03 株式会社ボナック 人工単一ガイドｒｎａ及びその用途
ES2853732T3 (es) * 2016-04-26 2021-09-17 Sumitomo Chemical Co Método de producción de un monómero para una molécula de ácido nucleico monocatenario
JP7188087B2 (ja) * 2017-02-06 2022-12-13 日産化学株式会社 一本鎖オリゴヌクレオチド
US20200038427A1 (en) 2017-03-31 2020-02-06 Bonac Corporation Cyclic nucleic acid molecule having gene expression control function
WO2018199338A1 (ja) * 2017-04-27 2018-11-01 国立大学法人広島大学 Ｂ型肝炎治療用核酸分子
WO2019022257A1 (ja) * 2017-07-28 2019-01-31 杏林製薬株式会社 線維症治療剤
WO2019074110A1 (ja) 2017-10-13 2019-04-18 株式会社ボナック 一本鎖核酸分子およびその製造方法
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
EP3770256A4 (en) 2018-03-20 2021-12-22 Tokyo Institute of Technology ANTISENSE OLIGONUCLEOTIDE WITH REDUCED TOXICITY
US20210115485A1 (en) * 2018-03-30 2021-04-22 Sumitomo Chemical Company, Limited Method for producing single-strand rna
EP3778886A4 (en) 2018-03-30 2022-11-02 Toray Industries, Inc. Method for producing hairpin single-stranded rna molecule
US11401296B2 (en) 2018-04-24 2022-08-02 Sumitomo Chemical Company, Limited Amidite compound and method for producing polynucleotide using said compound
CN112673102A (zh) * 2018-10-02 2021-04-16 东丽株式会社 发夹型单链rna分子的制备方法
WO2020152869A1 (ja) 2019-01-25 2020-07-30 杏林製薬株式会社 線維症治療剤
WO2020202952A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
JP7368456B2 (ja) 2019-03-29 2023-10-24 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
US12371451B2 (en) 2019-03-29 2025-07-29 Sumitomo Chemical Company, Limited Inorganic porous carrier and method for producing nucleic acids using same
US12378275B2 (en) 2019-03-29 2025-08-05 Sumitomo Chemical Company, Limited Porous inorganic carrier and method for producing nucleic acid using same
EP3950695A4 (en) 2019-03-29 2023-01-25 Sumitomo Chemical Company, Limited PROCEDURE FOR PRODUCTION OF RNA
CN114502566B (zh) 2019-10-11 2025-02-11 住友化学株式会社 核酸寡聚物的制造方法
CN115003680B (zh) 2020-01-29 2025-01-28 住友化学株式会社 制备核酸寡聚物的方法
KR20220133878A (ko) 2020-01-29 2022-10-05 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
CN115335387A (zh) * 2020-03-27 2022-11-11 住友化学株式会社 核酸寡聚物的制造方法
EP4151597B1 (en) 2020-05-13 2026-04-15 Sumitomo Chemical Company, Limited Inorganic porous substrate, inorganic porous support, and nucleic acid production method
KR20230034969A (ko) 2020-07-09 2023-03-10 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
KR20230074205A (ko) * 2020-09-24 2023-05-26 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
EP4410770A4 (en) 2021-09-28 2026-03-25 Sumitomo Chemical Co PROCESS FOR THE PRODUCTION OF PURIFIED DICHLOROACETIC ACID
EP4488282A4 (en) 2022-03-23 2025-11-19 Sumitomo Chemical Co PROCESS FOR THE PRODUCTION OF NUCLEIC ACID OLIGOMERS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004090108A3 (en) * 2003-04-03 2006-01-12 Alnylam Pharmaceuticals Irna conjugates
WO2009076321A2 (en) * 2007-12-07 2009-06-18 Halo-Bio Rnai Therapeutics Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) * 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US6962906B2 (en) * 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1627061B1 (en) 2001-05-18 2009-08-12 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003072745A2 (en) * 2002-02-22 2003-09-04 Eshleman James R Antigene locks and therapeutic uses thereof
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
AU2003256857A1 (en) * 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
NL1022811C2 (nl) * 2003-02-28 2004-08-31 Fountain Patents B V Systeem en werkwijze voor opslag en transport van zeecontainers.
US7595301B2 (en) 2003-09-30 2009-09-29 Anges Mg, Inc. Staple type oligonucleotide and drug comprising the same
JP2008504840A (ja) * 2004-06-30 2008-02-21 アルニラム ファーマスーティカルズ インコーポレイテッド 非リン酸骨格結合を含むオリゴヌクレオチド
JP2008526213A (ja) 2004-12-30 2008-07-24 トッド エム． ハウザー， 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
ES2538217T3 (es) * 2007-03-21 2015-06-18 Brookhaven Science Associates, Llc Composiciones combinadas antisentido de horquilla y métodos para modular la expresión
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
EP2171089B1 (en) * 2007-06-25 2014-01-22 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
US20100317714A1 (en) * 2007-11-29 2010-12-16 Suzhou Ribo Life Science Co., Ltd Complex molecule interfering the expression of target genes and its preparing methods
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
EP2256191A4 (en) 2008-02-15 2011-07-06 Riken CYCLIC SINGLE NUCLEIC ACID COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
JP2010174915A (ja) 2009-01-27 2010-08-12 Toyota Motor Corp 高圧ガスタンク
JP5449815B2 (ja) 2009-03-26 2014-03-19 住友化学株式会社 偏光板の製造方法
JP2010269823A (ja) 2009-05-21 2010-12-02 British American Tobacco Japan Kk 喫煙品用容器
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
JP2011152381A (ja) 2010-01-25 2011-08-11 Ucom:Kk 箸置き
JP5555940B2 (ja) 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
WO2011132672A1 (ja) 2010-04-19 2011-10-27 独立行政法人理化学研究所 機能性核酸の安定化法
SG186899A1 (en) 2010-07-08 2013-02-28 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
ES2533129T3 (es) 2010-08-03 2015-04-07 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004090108A3 (en) * 2003-04-03 2006-01-12 Alnylam Pharmaceuticals Irna conjugates
WO2009076321A2 (en) * 2007-12-07 2009-06-18 Halo-Bio Rnai Therapeutics Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides

Also Published As

Publication number Publication date
ES2443346T3 (es) 2014-02-19
JPWO2012017919A1 (ja) 2013-10-03
WO2012017919A1 (ja) 2012-02-09
EP2674494B1 (en) 2014-12-17
ES2527660T3 (es) 2015-01-28
US8691782B2 (en) 2014-04-08
EP2674494A1 (en) 2013-12-18
EP2628801A1 (en) 2013-08-21
TWI572716B (zh) 2017-03-01
JP2013138681A (ja) 2013-07-18
CN103052711A (zh) 2013-04-17
EP2639307A2 (en) 2013-09-18
EP2436767A4 (en) 2012-05-09
CN104059911A (zh) 2014-09-24
US20140171633A1 (en) 2014-06-19
US9206422B2 (en) 2015-12-08
TW201219570A (en) 2012-05-16
JP5555346B2 (ja) 2014-07-23
US20120035246A1 (en) 2012-02-09
PT2674494E (pt) 2015-02-27
EP2639307A3 (en) 2014-02-05
DK2674494T3 (en) 2015-02-23
EP2639307B1 (en) 2015-03-04
HK1200460A1 (zh) 2015-08-07
ES2533129T3 (es) 2015-04-07
TW201615835A (zh) 2016-05-01
JP2013034470A (ja) 2013-02-21
KR20180040727A (ko) 2018-04-20
KR101894701B1 (ko) 2018-09-04
CN103052711B (zh) 2016-08-03
EP2628801B1 (en) 2015-01-07
US20140171486A1 (en) 2014-06-19
EP2436767A1 (en) 2012-04-04
CN104004018B (zh) 2017-01-04
ES2528285T3 (es) 2015-02-06
KR101894702B1 (ko) 2018-09-04
JP4965745B2 (ja) 2012-07-04
EP2639307A8 (en) 2014-04-30
TWI515294B (zh) 2016-01-01
KR20130095738A (ko) 2013-08-28
CN104004018A (zh) 2014-08-27
CN104059911B (zh) 2017-01-04
KR20180040728A (ko) 2018-04-20
HK1189910A1 (en) 2014-06-20
JP5261677B2 (ja) 2013-08-14
US9200278B2 (en) 2015-12-01
EP2436767B1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
KR101849798B1 (ko) 유전자 발현 제어를 위한 일본쇄 핵산 분자
KR101894702B1 (ko) 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
KR101674778B1 (ko) 아미노산 골격을 갖는 단일-가닥 핵산 분자
JP2013153736A (ja) ペプチド骨格を有する一本鎖核酸分子
WO2013077446A1 (ja) 遺伝子発現制御のための一本鎖核酸分子
JP2013055913A (ja) 遺伝子発現制御のための一本鎖ｒｎａ分子

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250412

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250412

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250412